Understanding how time perception affects the sense of self in schizophrenia

EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia

This study is testing how changes in feeling time and self-awareness affect people with schizophrenia to see if it can help predict and manage their symptoms better.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 68 (estimated)
• Ages: 18 Years to 60 Years
• Sex: All
• Sponsor: Centre Psychothérapique de Nancy (Academic / other)
• Locations: 1 site (Strasbourg)
• Trial ID: NCT05296720 on ClinicalTrials.gov

What this trial studies

This study investigates the disturbances in the sense of self and time perception in patients with schizophrenia. It aims to identify objective markers that can predict the onset of psychosis in individuals showing minimal symptoms. The methodology involves tactile stimulation and assessments of how patients utilize their perception of time to prepare for future events. By understanding these correlations, the study seeks to improve management strategies for at-risk individuals.

Who should consider this trial

Good fit: Ideal candidates for this study are individuals aged 18 to 60 who have minimal psychotic symptoms and are enrolled in a social security plan.

Not a fit: Patients with active substance use disorders or significant neurological conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this research could lead to better predictive tools for identifying individuals at risk of developing schizophrenia, allowing for earlier intervention.

How similar studies have performed: While the approach of using objective measures to assess disturbances in the sense of self is innovative, similar studies have shown promise in understanding psychosis risk factors.

Eligibility criteria

Inclusion Criteria:

* Male or Female;
* Age between 18 and 60 years inclusive;
* Subject who has dated and signed the consent form (guardian or custodian prior to the commencement of any trial-related procedures if applicable);
* Enrolled in a social security plan or beneficiary of such a plan.

Exclusion Criteria:

* Psychoactive substance use disorders (as defined by DSM-V);
* Use of benzodiazepines (in the period prior to inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months prior to inclusion; use of cannabis (THC) will be verified with a urine dipstick) or hallucinogenic substances (in the period prior to inclusion, for a duration equivalent to 5 half-lives of the product);
* Neurological pathology or sequelae;
* Attention deficit hyperactivity disorder (ADHD);
* A borderline personality disorder;
* Disabling sensory disorders;
* Person deprived of liberty or under court protection;
* Pregnant, parturient or nursing woman;
* Subject in a period of exclusion as defined by another clinical study.

Where this trial is running

Strasbourg

• Anne GIERSCH — Strasbourg, France (Recruiting)

Study contacts

• Principal investigator: Anne GIERSCH, MD, PhD — Institut National de la Santé Et de la Recherche Médicale, France
• Study coordinator: Anne GIERSCH, MD PhD

Conditions Schizophrenia